IgA nephropathy

New England Journal of Medicine

Volumn 347, Issue 10, 2002, Pages 738-748

  Donadio, James V ^a   Grande, Joseph P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AZATHIOPRINE; CORTICOSTEROID; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; GROWTH FACTOR; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; SIALIC ACID;

CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIAGNOSTIC TEST; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; TONSILLECTOMY; TONSILLITIS; URINALYSIS;

ADRENAL CORTEX HORMONES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIAGNOSIS, DIFFERENTIAL; FATTY ACIDS, OMEGA-3; GLOMERULONEPHRITIS, IGA; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION;

EID: 0037026702     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra020109     Document Type: Review

References (110)

1. Berger J, Hinglais N. Les depots intercapillaires d'IgA-IgG. J Urol Nephrol 1968;74:694-5.
2. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;245:709-27
3. Julian BA, Waldo FB, Rifai A, Mestecky J. IgA nephropathy, the most common glomerulonephritis worldwide: a neglected disease in the United States? Am J Med 1988;84:129-32.
4. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988;12:340-7.
5. Emancipator SN. IgA nephropathy: morphologic expression and pathogenesis. Am J Kidney Dis 1994;23:451-62.
6. Habib R, Niaudet P, Levy M. Schönlein-Henoch purpura nephritis and IgA nephropathy. In: Tisher C, Brenner BM, eds. Renal pathology. Philadelphia: J.B. Lippincott, 1994:472-523.
7. Rai A, Nast C, Adler S. Henoch-Schonlein purpura nephritis. J Am Soc Nephrol 1999;10:2637-44.
8. D'Amico G, Colasanti G, Barbiano di Belgioioso G, et al. Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. Semin Nephrol 1987;7:355-8.
9. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207.
10. Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 1994;73:79-102.
11. Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA. Prognostic indicators in children with IgA nephropathy - report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 1994;8:15-20.
12. Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsyproven glomerulonephritis in Australia. Nephrol Dial Transplant 2001;16:1364-7.
13. Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000;35:157-65.
14. Jennette JC, Wall SD, Wilkman AS. Low incidence of IgA nephropathy in blacks. Kidney Int 1985;28:944-50.
15. Seedat YK, Nathoo BC, Parag KB, Naiker IP, Ramsaroop R. IgA nephropathy in blacks and Indians of Natal. Nephron 1988;50:137-41.
16. The New Zealand Glomerulonephritis Study: introductory report. Clin Nephrol 1989;31:239-46.
17. Hoy WE, Smith SM, Hughson MD, Megill DM. Mesangial proliferative glomerulonephritis in southwestern American Indians. Transplant Proc 1989;21:3909-12,
18. O'Connell PJ, Ibels LS, Thomas MA, Harris M, Eckstein RP. Familial IgA nephropathy: a study ofrenal disease in an Australian aboriginal family. Aust N Z J Med 1987;17:27-33.
19. Berthoux F. Incidence annuelle des glomérulonéphrites en 1987/1988 dans la région Rhône-Alpes élargie. Presse Med 1990;19:1417
20. Frimat L, Bellou-Zerrouki M, Kessler M. Incidence annuelle de la néphropathie à IgA (maladie de Berger) et du purpura d'Henoch-Schönlein dans l'Est de la France. Presse Med 1994;23:1879.
21. Simon P, Ramee MP, Autuly V, et al. Epidemiology of primary glomerular diseases in a French region: variations according to period and age. Kidney Int 1994;46:1192-8.
22. Tiebosch AT, Wolters J, Frederik PF, van der Wiel TW, Zeppenfeldt E, van Breda Vriesman PJ. Epidemiology of idiopathic glomerular disease: a prospective study. Kidney Int 1987;32:112-6.
23. Rambausek M, Rauterberg EW, Waldherr R, Demaine A, Krupp G, Ritz E. Evolution of IgA glomerulonephritis: relation to morphology, immunogenetics, and BP. Semin Nephrol 1987;7:370-3.
24. Stratta P, Segoloni GP, Canavese C, et al. Incidence of biopsy-proven primary glomerulonephritis in an Italian province. Am J Kidney Dis 1996;27:631-9.
25. Wyatt RJ, Julian BA, Baehler RW, et al. Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994: Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project. J Am Soc Nephrol 1998;9:853-8.
26. Smith SM, Tung KS. Incidence of IgA-related nephritides in American Indians in New Mexico. Hum Pathol 1985;16:181-4.
27. Kitagawa T. Lessons learned from the Japanese nephritis screening study. Pediatr Nephrol 1988;2:256-63.
28. Hsu SI, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 2000;57:1818-35.
29. Galla JH. Molecular genetics in IgA nephropathy. Nephron 2001;88:107-12.
30. Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000;26:354-7.
31. Ponticelli C, Traversi L, Feliciani A, Cesana BM, Banfi G, Tarantino A. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001;60:1948-54.
32. Koselj M, Rott T, Kandus A, Vizjak A, Malovrh M. Donor-transmitted IgA nephropathy: long-term follow-up of kidney donors and recipients. Transplant Proc 1997;29:3406-7.
33. Galla JH. IgA nephropathy. Kidney Int 1995;47:377-87
34. Jennette JC, Wieslander J, Tuttle R, Falk RJ. Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schönlein purpura: diagnostic value and pathogenic implications. Am J Kidney Dis 1991;18:466-71.
35. Russell MW, Mestecky J, Julian BA, Galla JH. IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 1986;6:74-86.
36. Mestecky J, Russell NW, Jackson S, Brown TA. The human IgA system: a reassessment. Clin Immunol Immunopathol 1986;40:105-14.
37. Lomax-Smith JD, Zabrowarny LA, Howarth GS, Seymour AE, Woodroffe AJ. The immunochemical characterization of mesangial IgA deposits. Am J Pathol 1983;113:359-64.
38. Bene MC, Faure GC. Mesangial IgA in IgA nephropathy arises from the mucosa. Am J Kidney Dis 1988;12:406-9.
39. Feehally J, Allen AC. Pathogenesis of IgA nephropathy. Ann Med Interne (Paris) 1999;150:91-8.
40. Olive C, Allen AC, Harper SJ, Wicks AC, Feehally J, Falk MC. Expression of the mucosal gamma delta T cell receptor V region repertoire in patients with IgA nephropathy. Kidney Int 1997;52:1047-53.
41. Harper SJ, Pringle JH, Wicks AC, et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int 1994;45:836-44.
42. Layward L, Allen AC, Hattersley JM, Harper SJ, Feehally J. Elevation of IgA in IgA nephropathy is localized in the serum and not saliva and is restricted to the IgA1 subclass. Nephrol Dial Transplant 1993;8:25-8.
43. Bene MC, Canton P, Amiel C, May T, Faure G. Absence of mesangial IgA in AIDS: a postmortem study. Nephron 1991;58:240-1.
44. Kilgore LL, Patterson BW, Parenti DM, Fisher WR. Immune complex hyperlipidemia induced by an apolipoprotein-reactive immunoglobulin A paraprotein from a patient with multiple myeloma: characterization of this immunoglobulin. J Clin Invest 1985;76:225-32.
45. Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993;104:172-82.
46. Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997;52:509-16.
47. Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001;60:969-73.
48. Mestecky J, Hashim OH, Tomana M. Alterations in the IgA carbohydrate chains influence the cellular distribution of IgA1. Contrib Nephrol 1995;111:66-71.
49. Julian BA, Tomana M, Novak J, Mestecky J. Progress in the pathogenesis of IgA nephropathy. Adv Nephrol Necker Hosp 1999;29:53-72.
50. Allen AC, Topham PS, Harper SJ, Feehally J. Leukocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant 1997;12:701-6.
51. Roccatello D, Picciotto G, Torchio M, et al. Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients: the role of asialoglycoprotein receprors. Lab Invest 1993;69:714-23.
52. Tomana M, Kulhavy R, Mestecky J. Receptor-mediated binding and uptake of immunoglobulin A by human liver. Gastroenterology 1988;94:762-70.
53. Libetta C, Rampino T, Palumbo G, Esposito C, Dal Canton A. Circulating serum lectins of patients with IgA nephropathy stimulate IL-6 release from mesangial cells. J Am Soc Nephrol 1997;8:208-13.
54. Amore A, Cavallo F, Bocchietto E, et al. Cytokine mRNA expression by cultured rat mesangial cells after contact with environmental lectins. Kidney Int Suppl 1993;43:S41-S46.
55. Ruef C, Budde K, Lacy J, et al. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 1990;38:249-57.
56. Taniguchi Y, Yorioka N, Oda H, Yamakido M. Platelet-derived growth factor, interleukin (IL)-1 beta, IL-6R and tumor necrosis factor-alpha in IgA nephropathy: an immunohistochemical study. Nephron 1996;74:652-60.
57. Niemir ZI, Stein H, Noronha IL, et al. PDGF and TGF-beta contribute to the natural course of human IgA glomerulonephritis. Kidney Int 1995;48:1530-41.
58. Grande JP. Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med 1997;214:27-40.
59. Yoshioka K, Takemura T, Murakami K, et al. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;68:154-63.
60. Taniguchi Y, Yorioka N, Masaki T, Asakimori Y, Yamashita K, Yamakido M. Localization of transforming growth factors betal and beta 2 and epidermal growth factor in IgA nephropathy. Scand J Urol Nephrol 1999;33:243-7.
61. Donadio JV, Grande JP. Immunoglobulin A nephropathy: a clinical perspective. J Am Soc Nephrol 1997;8:1324-32.
62. Fofi C, Pecci G, Galliani M, et al. IgA nephropathy: multivariate statistical analysis aimed at predicting outcome. J Nephrol 2001;14:280-5.
63. Donadio JV, Bergstralh EJ, Offord KP, Holley KE, Spencer DC. Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Clin Nephrol 1994;41:65-71.
64. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol 2000;11:2395-403.
65. Nicholls KM, Fairley KF, Dowling JP, Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med 1984;53:227-50.
66. Bogenschutz O, Bohle A, Batz C, et al. IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol 1990;10:137-47.
67. Johnston PA, Brown JS, Braumholtz DA, Davison AM. Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy: a report from the MRC Glomerulonephritis Registry. Q J Med 1992;84:619-27
68. Rekola S, Bergstrand A, Bucht H. IgA nephropathy: a retrospective evaluation of prognostic indices in 176 patients. Scand J Urol Nephrol 1989;23:37-50.
69. Alamartine E, Sabatier J-C, Guerin C, Berhet J-M, Berthoux E Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991;18:12-9.
70. Katafuchi R, Oh Y, Hori K, et al. An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin Nephrol 1994;41:191-8.
71. Schmidt S, Stier E, Hartung R, et al. No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995;26:727-31.
72. Schena FP, D'Altri C, Cerullo G, Manno C, Gesualdo L. ACE gene polymorphism and IgA nephropathy: an ethnicaily homogeneous study and a meta-analysis. Kidney Int 2001;60:732-40.
73. Varis J, Rantala I, Pasternack A, et al. Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol 1993;46:607-10.
74. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990;89:209-15.
75. Usui J, Yamagata K, Kai H, et al. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Intern Med 2001;40:697-702.
76. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002;13:1100-8.
77. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-40.
78. Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994;9:265-9.
79. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 1995;111:184-92.
80. Cheng I, Fang G, Wong M, Ji Y, Chan K, Yeung H. A randomized prospective comparison of nadolol, captopril with or without ticlodipine on disease progression in IgA nephropathy. Nephrology 1998;4:19-26.
81. Cattran DC, Greenwood C, Ritchie S. Long-term benefit of angiotensin-converting enyzme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:247-54.
82. Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-6.
83. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
84. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883-7.
85. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986;26:174-80.
86. Shoji T, Nakanishi I, Suzuki A, et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 2000;35:194-201.
87. Locatelli F, Pozzi C, Del Vecchio L, et al. Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomised multicentre trial. J Nephrol 1999;12:308-11.
88. Grande JP, Donadio J. n-3 Polyunsaturated fatty acids in the treatment of patients with IgA nephropathy. In: Kremer J, ed. Medicinal fatty acids in inflammation. In: Progress in inflammation research. Basel, Switzerland: Birkhauser, 1998:125-40.
89. Grande JP, Walker HJ, Holub BJ, et al. Suppressive effects offish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 2000;57:1027-40.
90. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. Lancet 1984;1:1017-8.
91. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial offish oil in IgA nephropathy. N Engl J Med 1994;331:1194-9.
92. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentaenoic acid (EPA): a two year prospective trial. Clin Nephrol 1989;31:128-31.
93. Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol 1994;41:183-90.
94. Cheng IKP, Chan PCK, Chan MK. The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 1990;5:241-6.
95. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997;8:1739-44.
96. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 1999;10:1772-7.
97. Donadio JV Jr, Larson TS, Bergstalh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001;12:791-9.
98. Hogg RJ. A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Am J Kidney Dis 1995;26:792-6.
99. Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl 1999;70:S56-S62.
100. Glassock RJ. The treatment of IgA nephropathy: status at the end of the millennium. J Nephrol 1999;12:288-96.
101. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13:142-8.
102. Bene MC, Hurault de Ligny B, Kessler M, Foliguet B, Faure GC. Tonsils in IgA nephropathy. Contrib Nephrol 1993;104:153-61.
103. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999;51:147-52.
104. Frohnert PP, Sterioff S. Twenty-five years of renal transplantation at Mayo Clinic. Clin Transpl 1989;1:267-74.
105. Frohnert PP, Donadio JV, Velosa JA, Holley KE, Sterioff S. The fate of renal transplants in patients with IgA nephropathy. Clin Transplant 1997;11:127-33.
106. Hene RJ, Velthuis P, van de Wiel A, Klepper D, Dothout Mees EJ, Kater L. The relevance of IgA deposits in vessel walls of clinically normal skin: a prospective study. Arch Intern Med 1986;146:745-9.
107. Rena G, Begg F, Ross A, et al. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic ampspecific phosphodiesterase PDE4A10. Mol Pharmacol 2001;59:996-1011.
108. Meadow SR, Scott DG. Berger disease: Henoch-Schönlein syndrome without the rash. J Pediatr 1985;106:27-32.
109. Kashtan C, Sibley R, Michael A, Vermer R. Hereditary nephritis: Alport syndrome and thin glomerular basement membrane disease. In: Tisher C, Brenner B, eds. Renal pathology. Philadelphia: J.B. Lippincott, 1994:1239-66.
110. Auwardt R, Savige J, Wilson D. A comparison of the clinical and laboratory features of thin basement membrane disease (TBMD) and IgA glomerulonephritis (IgA GN). Clin Nephrol 1999;52:1-4.